Health Economics›Follicular lymphoma›Relapsed or refractory, randomized data

Relapsed or refractory, randomized data

Follicular lymphoma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Bendamustine and Obinutuzumab Variant #02	—	R 107 792	28d	—	—	~5	~R 227 981 PFS proxy · indirect	2
Bendamustine monotherapy Variant #01	—	R 7 084	—	~16.5 mo	—	~8	~R 56 672 PFS proxy · indirect	2

2 of 2 regimens shown